ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

JK Rowling has been celebrating the Supreme Court judgment that trans women are not legally women - but actors who have ...

After California Gov. Gavin Newsom ordered the state to redo its EPR rules, companies have jumped in with specifics. One ask: Letting them tap a $5 billion plastic pollution fund to support greener ...

The City Justice Center opened in 2002. Since then, 45 people have died in custody, including 29 who were pronounced dead ...

The Pensacola News Journal is working with high schools in Escambia and Santa Rosa County to put their top students in the ...

Netflix is a rare media stock on the rise today as markets tank amid tariffs and President Donald Trump’s renewed vitriol ...

PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of PathAI's pathology universal transformer (PLUTO) foundation model and portfolio ...

Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will ...

After a Sebi probe, Gensol Engineering is now on the Enforcement Directorates radar. This and more in todays ETtech Morning ...

Around 250 students and faculty rallied on Ho Plaza on Thursday for the National Day of Action for Higher Ed, protesting the ...